SCHEMBL6036313

SCHEMBL6036313

OCc1cn(-c2ccc(C(F)(F)F)cn2)nc1C1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.40
ABL1 P00519 1/20 0.40
LMNA P02545 1/20 0.40
SMO Q99835 1/20 0.38
PPARD Q03181 1/20 0.36
GCGR P47871 2/20 0.36
GIPR P48546 1/20 0.36
CNR2 P34972 3/20 0.36
CNR1 P21554 2/20 0.36
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HDAC4 P56524 1/20 0.35
GCG P01275 3/20 0.35
CYP3A4 P08684 1/20 0.35
HMOX1 P09601 1/20 0.35
S100A4 P26447 1/20 0.35
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
KMT2A Q03164 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6034459 0.89 KDM4E (0.37) KDM4EABL1LMNASMOPPARD
SCHEMBL6036131 0.81 SMN1; SMN2 (0.46) KDM4EABL1LMNAGCGRGIPR
SCHEMBL6036081 0.80 KDM4E (0.40) KDM4EABL1LMNASMOPPARD
SCHEMBL6035773 0.79 PTGDR2 (0.38) KDM4EABL1LMNASMOGCGR
SCHEMBL6035122 0.77 SMN1; SMN2 (0.52) KDM4EABL1LMNAHPGDSMN1; SMN2
SCHEMBL718917 0.77 TMEM97 (0.38) KDM4EABL1LMNASMOCNR2
SCHEMBL3087656 0.77 NPC1 (0.43) KDM4EABL1LMNACNR2CNR1
SCHEMBL6034551 0.77 LMNA (0.40) KDM4EABL1LMNASMOPPARD
SCHEMBL6034557 0.77 LMNA (0.40) KDM4EABL1LMNASMOPPARD
SCHEMBL6036208 0.77 DGAT1 (0.41) PPARDGCGRGIPRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 KDM4E 509/4885ABL1 2860/4885LMNA 1816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.